Altre lingue Marksans Pharma Limited

Azioni

MARKSANS

INE750C01026

Prodotti farmaceutici

Mercato chiuso - NSE India S.E. Altri mercati azionari 12:49:45 05/12/2025			Variaz. 5gg	Var. 1 gen.
183,97 ^INR	-2,04%		-2,12%	-37,98%

20/11	Relonchem di Marksans Pharma ottiene l'autorizzazione del regolatore britannico per la soluzione di Cetirizina Dicloridrato	MT
20/11	Marksans Pharma: la filiale britannica ottiene l'autorizzazione alla commercializzazione della cetirizina	RE

Altre lingue

Marksans Pharma Arm Gets UK Regulator's Nod for Cetirizine Dihydrochloride Solution	20/11
Marksans Pharma says UK subsidiary receives marketing authorization for cetirizine	20/11
Marksans Pharma Arm Gets US FDA's Nod for Chronic Diarrhea Drug	19/11
Marksans Pharma unit receives USFDA approval for loperamide tablets	19/11
Marksans Pharma's Unit Gets Regulatory Nod to Market Mefenamic Acid Tablets in UK	17/11
Marksans Pharma says Relonchem receives UK MHRA approval for Mefenamic Acid tablets	17/11
Marksans Pharma Sept-quarter consol net profit 982.5 million rupees	13/11
Marksans Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	13/11
Marksans Pharma says US FDA conducted cGMP inspection at Marksans Pharma's Goa facility	10/11
Marksans Pharma Limited Provides Update on Inspection by US FDA	10/11
Marksans Pharma says Relonchem receives UK authorization for exemestane tablets	05/11
Marksans Pharma Arm Gets Marketing Authorization from UK Regulator for Two Products	15/10
Indian Equities End Flat on Tuesday as IT Weakness Offsets Auto Gains	23/09
Marksans Pharma Arm Gets Marketing Authorization for Moxonidine Tablets in UK	23/09
Indian Equities Rally on Monday on GST Reform Plans	18/08
Marksans Pharma Arm Gets UK Marketing Authorization for Metformin Hydrochloride Relonchem; Shares Up 3%	18/08
Marksans Pharma Limited Receives Marketing Authorization for Its Products	18/08
Indian Shares Edge Lower on Tuesday Ahead of US, Domestic Inflation Data	12/08
INDIA STOCKS-India's stock benchmarks inch lower ahead of inflation data	12/08
Marksans Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	12/08
Marksans Pharma's Consolidated Profit Declines in Fiscal Q1; Shares Plunge 14%	12/08
Marksans Pharma Arm Gets US FDA Nod for Omeprazole Delayed-Release Tablets	08/08
Marksans Pharma re-appointed Mark Saldanha as MD	25/07
Marksans Pharma re-appoints Mark Saldanha as managing director	25/07
Marksans Pharma Limited announces Annual dividend, payable on September 07, 2025	12/07

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Trascrizioni Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Marksans Pharma Limited

Azioni

MARKSANS

INE750C01026

Prodotti farmaceutici

Altre lingue

Filtri